Anti-cancer drugs potentially causing pericardial effusion include anthracyclines, cyclophosphamide, cytarabine, busulfan, tyrosine kinase inhibitors (TKI) used for treatment of chronic myelogenous leukemia (ponatinib, dasatinib, bosutinib and, to a smaller extent, nilotinib), arsenic trioxide, all-trans retinoic acid, and interleukin-2 [18–21]. Here, IL2 is linked to pericardial effusion.